1-hydroxy-2-pyridinones, process for their preparation and medicines containing them, as well as intermediates formed by the preparation of 1-hydroxy-2-pyridinones
1 claim: 1 independent, 0 dependent
- 1Processo para a preparação de compostos de formula I na qual 12 3 R , R e R~\ iguais ou diferentes, significam um átomo de hidrogénio ou um grupo alquilo de cadeia pequena com 1-4 áto 13 a mos de carbono» representando R e R » de preferência» um átomo de hidrogénio e R , de preferência um grupo metilo, X significa um átomo de enxofre ou de oxigénio, Y significa hidrogénio ou até 2 átomos de halogéneo, nomeada mente cloro e/ou bromo, Z significa uma ligação simples ou um grupo bivalente 0, S, -CRg- (R = H ou alquilo C^-C^) ou outro grupo bivalente com 2 - 10 átomos de carbono e eventualmente oxigénio e/ou enxofre ligados formando uma cadeia, na qual — quando o grupo contém 2 ou mais átomos de oxigénio e/ou de enxofre — estes devem estar separados por pelo menos 2 átomos de carbono e na qual 2 átomos de carbono vizinhos também podem estar ligados por uma ligação dupla e as valências livres dos átomos de carbono estão saturadas por hidrogénio e/ou grupos alquilo θ2θ4’ Ar significa um sistema cíclico aromático com até dois anéis, que podem estar substituídos por até três grupos de entre flúor, cloro, bromo, metoxi, alquilo 0,-0!,, trif luorometij. H* lo e trifluorometoxi, ó-halometil~2-pirona de fórmula III caracterizado por a) se fazer reagir uma III IV e se transformar a ariloximetilpirona ou ariltiometilpirona, assim obtida, de fórmula V por reacção com hidroxilamina, na hidroxipiridona de fórmula ou b) se fazer reagir uma dihalopicolina de fórmula VI com um fenol de fórmula IV, se oxidar o composto obtido ao N-óxido e se transformar o composto por saponificação do halogéneo do anel, para se obter um composto de acordo com a fórmula I, *1 p o em que, nas fórmulas III a VI, os grupos R , R , R , X, Y, Z e Ar possuem os mesmos significados que na fórmula I e Hal si gnifica um atomo de halogéneo, em especial cloro ou bromo, ou nos compostos obtidos de acordo com os processos a) ou b), ou nos produtos intermediários em que Ar ou o anel de piridona contêm ainda grupos reactivos, se introduzir, por troca com estes, outros substituintes, que obedecem às definições dos 12 3 grupos R , R , R e dos substituintes de Ar. - 2- Processo de acordo com a reivindicação 1, caracterizado por se obterem compostos de fórmula I, em que Ar significa o grupo fenilo, eventualmente substituído. - 3- Processo de acordo com a reivindicação 1, caracterizado por se obterem compostos de fórmula I, em que Ar representa um sistema bicíclico isolado, de preferência derivado de bifenilo, difenilalcano ou difeniléter, que está, con forme o caso, substítuido. Processo de acordo com uma ou mais das reivin dicaçoes 1 a 3» caracterizado por se obterem compostos de fór mula I, em que Z é uma ligação simples. - Processo de acordo com uma ou mais das reivin dicaçoes 1 a 3, caracterizado por se obterem compostos de fór mula I, em que Z representa ou contém um átomo de oxigénio. - 6» Processo de acordo com a reivindicação 1, caracterizado por se obter 6-/5-(4-clorofenoxi)-fenoximetil7”l” -hidroxi-4-metil-2-piridona (= composto de fórmula I de acor1 3 do com a definição na reivindicação 1, com R β R = Y β H, R » CH^, X = 0, Z = 0 na posição 4 em relação ao grupo XCHge Ar = Cl-<^ . - 7 a Processo de acordo com a reivindicação 1, caracterizado por se obter 6-(bifenilil-4-oximetil)-l-hidroxi-4-metil-2-piridona (= composto de fórmula I de acordo com a 13 2 definição na reivindicação 1, com R = R= Y = H, R = CH^, X ss Ο, Z = ligação simples e Ar = na posição 4 em relação ao grupo XCHg-). - 8» Processo de acordo com a reivindicação 1, caracterizado por se obter l-hidroxi-4-metil-ó-/5-(4-trifluorometilfenoxi)-fenoximetil/-2-piridona ( = composto de fórmula I de acordo com a definição na reivindicação 1, com R =R =Y=H, R = CH^, X = 0, Z = 0 na posição 4 em relação ao grupo XCH^e Ar = F 3 C-^-\). Processo de acordo com uma ou mais das reivin dicações 1 a 8, caracterizado por, na alternativa de processo a), se efectuar a transformação da ariloximetilpirona ou da ariltiometilpirona de fórmula V na hidroxipiridona de fórmula X, por meio de uma reacção com pelo menos cerca de 1 Mole de um sal de hidroxilamónio por Mole de composto de fórmula V, na presença de pelo menos cerca de 1 equivalente de pelo menos uma base orgânica ou inorgânica, calculado em relação ao sal de hidroxilamónio. - 105 Processo de acordo com a reivindicação 9, caracterizado por se utilizar como bases os carbonatos e/ou hidro geno carbonato s de metais alcalinos, de preferência de sódio e/ou de potássio, em particular Na^CO^. Processo de acordo com a reivindicação 10, ca racterizado por se utilizar como sal de hidroxilamónio o sulfato de hidroxilamónio. 125 Processo para a preparação de composições far macêuticas caracterizado por se incorporar como ingrediente activo, pelo menos um composto de fórmula I, quando preparado de acordo com qualquer das reivindicações 1 a 11, ou pelo menos um sal desse composto com uma base inorgânica ou orgânica, fisiolègicamente assimilável, com um veículo farmacêutico fisiolõgicamente assimilável e, conforme o caso, com outros adi tivos e/ou adjuvantes farmacêuticos, de modo a obter uma forma de administração adequada. - 13- Processo para a preparação de compostos de fórmula V dos nas reivindicações 1 a 8, caracterizado por se fazer reagir uma 6-halometil-2-pirona de fórmula IXI X 2 3 em que, nestas formulas, os grupos R , R , R , X, Y, Z e Ar possuem os significados mencionados nas reivindicações 1 a 8 e Hal representa um átomo de halogéneo, em particular de cloro ou de bromo. A requerente declara que os primeiros pedidos desta patente foram depositados na República Federal Alemã em 18 de Abril de Ip86 e em 2 de Agosto de 1986, sob os números P 36 13 O6I.3 e P 36 26 211.0, respectivamente.
254 paragraphs in 12 sections, as filed
Patent Specification for the German, Industrial and Commercial HOECHST AKTIENGESELLSCHAFT Patent, Headquartered in D-6230 Frankfurt / Main 80, Federal Republic of Germany (inventors: Dr. Gerhard Lohaus, Dr. Walter Dittmar, Dr. Heinz Hanel, Dr. Wolfgang Raether,
Dr. Dieter Reuschling, Dr. Bengt-Thomas Grobel, residing in the Federal Republic of Germany), FOR PREPARATION PROCESS<sup>0 P £</sup> 1-HYDRQXI-2-PYRIDES,
PHARMACEUTICAL COMPOSITIONS
CONTAINING THEM AND PRODUCTS
INTERMEDIARIES FOR YOUR PREPARATION ”.
OBJECTIVE OF THE INVENTION The novel invention is novel 1-hydroxy-2-pyridones of formula I (see claim 1), their application in combating mainly fungal and yeast infections, as well as medicaments containing these compounds; It is a further object of the invention special intermediate products formed in the preparation of the novel 1-hydroxy-2-pyridones.
DE-PS 22 3 ^ 009 are known compounds of formula II
<img file="PT84702B_D0001.tif" />
II wherein R R is, inter alia, an aryloxyalkyl or arylmercaptoalkyl group having alkyl of 1-4 carbon atoms. These groups are specifically exemplified only as phenoxy methyl or phenylmercaptomethyl. In addition to aryloxyalkyl or arylmercaptoalkyl, R may also, according to DE-PS 22 34 009, represent different groups such as aryl, aryl alkyl with 1-4 carbon atoms, arylalkenyl with 2-4 alkenyl alkenyl. carbon, benzhydryl and phenylsulfonylalkyl having alkyl of 1-4 carbon atoms. Where for these groups specifications are given in the mentioned patents, these are generally - with the exception of the aryl group itself, which may also be referred to as naphthyl - only phenyl groups which, as the case may be, may be substituted by 1-alkyl groups. -4 carbon atoms, 1-4 carbon alkoxy groups, nitro, cyano or halogen groups.
In contrast, the invention relates to 1-hydroxy-2-pyridone derivatives in which the substituent at position -6 (R<sup>1</sup> in formula II) contains an aromatic system containing at least two optionally substituted aromatic rings and is attached via an oxymethyl or thiomethyl group to the pyridone group described in general formula I.
An object of the invention is therefore the 1-hydroxy-2-pyridones of general formula I (see claim 1), wherein
R 1, R 2 and R 2, the same or different, means a hydrogen atom or a small chain alkyl group having 1-4 carbon atoms, where R is<sup>4</sup> and R, preferably a hydrogen atom 2 and R, preferably a methyl group,
X means a sulfur or oxygen atom,
Y means a hydrogen atom or up to 2 halogen atoms, namely chlorine and / or bromine, means a single bond or a divalent group O, S, -CRg- (R = H or C1 -C4 alkyl) or other group bivalent with 2-10 carbon atoms and optionally oxygen and / or sulfur bonded to form a chain, where - when the group contains 2 or more oxygen and / or sulfur atoms - these must be separated by at least 2 carbon atoms and in which two neighboring carbon atoms may also be linked by a double bond and the valences li from carbon atoms are saturated with hydrogen and / or alkyl groups
Ar means a cyclic aromatic system of up to 2 rings, which may be substituted by up to 3 groups, equal or different, from fluorine, chlorine, bromine, methoxy, C1 -C4 alkyl, trifluoromethyl and trifluoromethoxy.
In the Z groups, the carbon chain members are preferably -CH2 - groups.<sup>re</sup>f<sup>erem</sup>“<sup>if your</sup>e? CH ^ e constituents
Examples of healthy Z groups
-0-, -S-, -CH<sub>2</sub>-, - (CH<sub>2</sub>)<sub>m</sub>- (m = 2-10), -C (CH<sub>3</sub>)<sub>2</sub>-, -ΟΗ ,, Ο-, och<sub>2</sub>-, -GHgS-, -sch<sub>2</sub>-, -sch (c<sub>2</sub>H<sub>5</sub>) -, -ch = ch-ch<sub>2</sub>o-, -0-CH<sub>2</sub>-CH = CH-CH<sub>2</sub>0-, -OCHgCHgO-, -OCHgCHgCE4O-, -SCHgCHgC2S-, -SCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>0-, -SCH<sub>2</sub>CH<sub>2</sub>0CH<sub>2</sub>CH<sub>2</sub>0-, -SCH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>O-C ^ CIC ^S-, -S-CH<sub>2</sub>-c (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-S-, etc.
The term cyclic aromatic system includes the phenyl group and condensed systems such as naphthyl, tetrahydronaphthyl and indenyl as well as isolated systems such as biphenyl, diphenylalkane, diphenylether and diphenylthioether derivatives.
Important representatives of the class of compounds characterized by formula I are for example 6- [5- (4-chlorophenoxy) phenoxymethyl] -1-hydroxy-4-methyl-2-pyridone, melting point (mp) 1667 ° C (1 )} 6- / 5- (2,4-dichlorophenoxy) -phenoxymethyl-1-hydroxy-4-methyl-2-pyridone, mp 162 ° C (2)} 6- (biphenylyl-4-oxymethyl) -1 -hydroxy-4-methyl-2-pyridone, mp 184 ° C (3)} 6- (4-benzylphenoxymethyl) -1-hydroxy-4-methyl-2-pyridone, mp 194 ° C (4); 6- / 5- (2,4-dichlorobenzyloxy) phenoxymethyl-1-hydroxy-4-methyl-2-pyridone, mp 172 ° C (5) 5 6- [5- (4-chlorophenoxy) phenoxymethyl] -1-hydroxy-3,4-dimethyl-2-pyridone, mp 155 ° C (6); 6- [5- (2,4-dichlorobenzyl) phenoxymethyl] -1-hydroxy-3,4-dimethyl-2-pyridone, mp 169 ° C (7)} 6-5- (cinnamyloxy) phenoxymethyl / -1-hydroxy-4-methyl-2-pyridone; mp 179 ° C (8); 1-hydroxy-4-methyl-6- [5- (4-trifluoromethylphenoxy) -phenoxymethyl] -2-pyridone, mp 145Â ° C (9) »1-hydroxy-4-methyl-6-5- (naphtho-methyl) 1-ylmeloxy) -phenoxymethyl-2-pyridone, mp 179 ° C (io); 6- [5- (4-chlorophenoxy) phenoxymethyl] -1-hydroxy-4,5-dimethyl-2-pyridone (11); 6- [5- (4- (4-chlorophenoxy) phenoxymethyl) phenoxymethyl] -1-hydroxy-4-methyl-2-pyridone, mp 158 ° C (12); 6- [2,6-dichloro-4- (naphtho-2-ylthiomethyl) -phenoxymethyl] -1-hydroxy-4-methyl-2-pyridone, mp 138 ° C (13); 6- / 2,6-dichloro-4- (4-phenylphenoxymethyl) -phenoxymethyl-1-hydroxy-4-methyl-2-pyridone, mp 19θ ° 0 (14); 6- / 5- (4-chlorobenzyloxy) -phenoxymethyl7-1-hydroxy-4-methyl-2-pyridone, mp 173 ° C (15) -1-hydroxy-4-methyl-6- [5- (4-trifluoromethoxybenzyloxy) phenoxymethyl] -2-pyridone, mp 143 ° C (16); 6- [5- (4-tert-butylbenzyloxy) -phenoxymethyl] -1-hydroxy-4-methyl-2-pyridone, mp 181 ° C (17)} 6- / 2- (4-chlorobenzyloxy) -phenoxymethyl / - 1-hydroxy-4-methyl-2-pyridone, mp 161 ° C (18); 1-hydroxy-4-methyl-6- [2- (naphtho-1-ylmethoxy) phenoxymethyl] -2-pyridone, mp 15θ ° θ (19) -1-hydroxy-4-methyl-6-3- ( naphtho-1-ylmethoxy) -phenoxymethyl / -2-pyridone, mp 155 ° C (20); 6- [3- (4-chlorobenzyloxy) phenoxymethyl] -1-hydroxy-4-methyl-2-pyridone, mp 145 ° C (21); 6- [5- (4-chlorophenoxy) phenoxymethyl] -1-hydroxy-2-pyridone, mp 180 °
C (22)} 6- / 2,6-dichloro-4- (4-chlorophenoxy) phenoxymethyl-1-hydroxy-4-methyl-2-pyridone, mp 15θ ° 0 (23)} 6- (4 -benzyloxy-2,6-dichlorophenoxymethyl) -1-hydroxy-4-methyl-2-pyridone, mp 161 ° C (24); 6- (2,6-dichloro-4-phenylphenoxymethyl) -1-hydroxy-4-methyl-24
-pyridone, mp 195 ° C (25); 6- [5- (4-bromo-2-chlorophenoxy) phenoxymethyl] -hydroxy-5-methyl-2-pyridone, mp 175 ° C (26); 1-hydroxy-5-methyl-6- [5- (3,5,5-trimethoxybenzyloxy) phenoxymethyl] -2-pyridone, mp 155 ° C (27), 6-5- (2,5-dichlorobenzyl) -phenoxymethyl-1-hydroxy-4-methyl-2-pyridone, mp 173 ° C (28); 6- [2,6-dibromo-4- (4-chlorophenoxy) phenoxymethyl] -1-hydroxy-5-methyl-2-pyridone (29); 6- (2,6-dibromo-4-phenylphenoxymethyl) -1-hydroxy-4-methyl-2-pyridone (30); 6- (2-bromo-4-phenylphenoxymethyl) -1-hydroxy-5-methyl-2-pyridone, mp 245 ° C (31), 6- (2-bromo-6-chloro-4-phenylphenoxymethyl) -1 -hydroxy-5-methyl-2-pyridone (32); 6- [5- (4-fluorophenoxy) phenoxymethyl] -1-hydroxy-4-methyl-2-pyridone, mp 155 ° C (33) 5 6- [3- (5-chlorophenylthio) phenoxymethyl] -1-hydroxy-4-methyl-2-pyridone (35); 1-hydroxy-5-methyl-6- [3- (naphtho-1-ylmethylthio) -phenoxymethyl] -2-pyridone, mp 154 ° C (35) *, 1-hydroxy-4-methyl-6- [1] 3- (naphtho-1-ylmethoxy) phenylthiomethyl-2-pyrido, mp 163 ° C (36); 1-hydroxy-4-methyl-6- (2-phenylphenoxymethyl) -2-pyridone, mp 179 ° C (37) 5 6- (2-benzylphenoxymethyl) -1-hydroxy-4-methyl-2-pyridone, mp 155 ° C (38); 1-hydroxy-3,5-dimethyl-6- [3- (naphtho-1-ylmethylthio) phenoxymethyl] -2-pyridone, mp 1553 ° C (39) 5-6- (2,4-dibromo-6-phenylphenoxymethyl) -1-hydroxy-4-methyl-2-pyridone, mp 13θ ° 0 (5θ); 6- [5- (4- (4-chlorophenoxy) phenoxy) phenoxymethyl] -1-hydroxy-4-methyl-2-pyridone, mp 100 ° C (5l);
6- [3- (4-chlorobenzyloxy) phenylthiomethyl] -1-hydroxy-4-methyl-2-pyridone, mp 95 ° C (52); 6- [5- (4-chlorophenylthio) phenoxymethyl] -1-hydroxy-5-methyl-2-pyridone, mp 15θ ° θ (53); 1-hydroxy-6- [3- (4-methoxyphenylthio) phenoxymethyl] -4-methyl-2-pyridone, mp 162<sup>O</sup>C (54); 1-hydroxy-4-methyl-6- [3- (phenoxyethoxy) phenoxymethyl] -2-pyridone, mp 148 ° C (55) 5 6-5- (4-chlorophenoxypropoxy) -phenoxymethyl7-1-hydroxy-5 -methyl-2-pyridone, mp 126-2 ° C (56 ° C); 6- [3- (5-chlorophenylthiopropylthio) phenoxymethyl] -1-hydroxy-4-methyl-2-pyridone, mp 102 ° C (57), 6-3- (4-chlorophenylthiobutoxy) phenoxymethyl / - 1-hydroxy-4-methyl-2-pyridone, mp 104 ° C (58); 6- [3- (5-chlorophenylthio ethoxyethoxy) phenoxymethyl] -1-hydroxy-5-methyl-2-pyridone, mp 98 ° C (59); 6- [5- (O (N -dimethyl-4-methoxybenzyl) phenoxymethyl] -1-hydroxy-4-methyl-2-pyridone, mp 156Â ° C (50); - (5-chlorophenylthio) -2,2-dimethylpropane-3-ylthio-phenoxymethyl-1-hydroxy-4-methyl-2-pyridone, mp 135 ° C (5l);
- 5-6- 4- [1- (4-chlorophenyl) butene-2-4-yloxy-phenoxymethyl] -1-hydroxy-4-methyl-2-pyridone, mp 167-6 ° C (52) ; 6- [3- (4-chlorophenylthioethoxyethoxyethylthio) -phenoxymethyl] -1-hydroxy-4-methyl-2-pyridone, mp 95 ° C (53) phenoxymethyl-1-hydroxy-4-methyl-2-pyridone mp 159 ° C (5%);
The preparation of the compounds according to the invention may be carried out by various methods known per se, for example by reaction of 6-halomethyl-2-pyrones of formula III (see claim 1) with appropriate phenols or thiophenols, optionally of formula IV (see claim 1) and transformation of the formed aryloxymethylpyrones or arylthiomethylpyrones of formula V (see claim 1) to hydroxypyridones by reaction with hydroxylamine. Alkylations are conveniently carried out in practical or aprotic solvents such as methanol, ethanol, isopropanol, acetone, acetonitrile, ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, dimethylformamide, or dimethyl sulfoxide, with aprotic solvents being preferred. To capture the released hydrogen halide, inorganic or organic bases such as sodium or potassium hydroxide, sodium, potassium or calcium carbonate, triethylamine, tributylamine, pyridine, 4-dimethylaminopyridine, diazabicyclononane, N-methylpiperidine are used. others in at least equivalent quantities. Reaction temperatures are generally between room temperature and about 80 ° C; in special cases, however, appreciably higher or lower temperatures such as about 110 ° C or 0 ° C may also be advantageous.
For the transformation of 2-pyrones to 1-hydroxy-2-pyridones, hydroxylamine is reacted, generally in the form of its inorganic or organic salts or acids, preferably hydrochloric, sulfuric or acetic acids, in the presence of at least about one equivalent of a base, calculated in relation to the hydroxylammonium salt. The amount of hydroxylamine salt is at least about 1 mole relative to the amount of pyrone used, however, it is convenient to increase the reaction rate and yield by using an excess of about 2 and 10 mole, relative to 1 mole of pyrone, and further add this amount in several portions during the course of the reaction. Bases for this reaction are inorganic as well as organic bases. Preferred organic bases are aminopyridine (derivatives) and imidazole (derivatives) such as 2-aminopyridine, 2-amino picoline, 2-methylaminopyridine, imidazole and 2-methylimidazole; Preferred inorganic bases are alkali metal carbonates and / or bicarbonates (LigCO ^, Na ^CO ^, K ^CO CO, NaHCO ^, KHCO ^, RbgCO ^, CsHCO ^, etc.). Of the inorganic bases mentioned, sodium and potassium carbonates and bicarbonates, particularly Na 2 CO 4, are particularly suitable.
Organic bases are generally employed in amounts of from about 1 to 20 Mole, preferably from about 3 to 10 Mole per Mole of the pyrone used and may simultaneously serve as a solvent; thus the requirement is also generally met when at least about 1 base equivalent is used with respect to the amount of the hydroxyammonium salt used.
Of course, mixtures of these bases may also be employed to lower the melting temperature of the system when working at low temperatures is required. In general, the reaction temperatures are from about 20 to 150 ° C, preferably from about 50 to 100 ° C.
If inorganic bases are employed, as in the case of organic bases, the amount of hydroxylammonium salt, at least a substantially equivalent amount of base, is added for convenience. Per Mole of hydroxylammonium chloride is used for example at least 1/2 Mole of NagCO4 or 1 Mole of NaHCO4. Inorganic bases may also be employed either alone or in any mixture.
<img file="PT84702B_D0002.tif" />
In carrying out the variant with inorganic bases, advantageously the 2-pyrone is mixed with the hydroxylammonium salt - in this case preferably hydroxylammonium sulfate - and the alkaline carbonate and / or hydrogen carbonate, and the crystalline mass obtained until the pyrone is consumed; The 2-pyridone obtained may be isolated after separation of the inorganic salts, directly or, even better, as a salt of an organic base, for example as an ethanolamine salt.
The temperature at which this variant is processed must in no case exceed 120 ° C. It should conveniently be above about 50 ° C, preferably between about 6 ° and 105 ° C.
It is also possible in both the organic based and inorganic based variants to use inert solvents or diluents. In general this is not necessary, but may in certain cases bring advantages. When solvents or diluents are used, they are generally employed only in small amounts, at most up to about by weight of the total reaction mixture. Preferably, such amounts are about 3 to 15% by weight.
The solvents or diluents may be polar or supportive, miscible or immiscible with water. For example, the following substances may be employed: water, low molecular weight alcohols such as methanol, ethanol, isopropanol, ethylene glycol, ethylene glycol monomethyl ether and propylene glycol, carboxylic acid amides such as dimethylformamide and diethylformamide, ethers such as diisopropyl ether, chlorinated hydrocarbons such as chlorobenzene , nitrite such as acetonitrile, hydrocarbons aliphatic, cycloaliphatic or aromatic.
The preparation of 6-halomethyl-2-pyrones, especially chlorinated ones, may for example be carried out by the procedure described in Chemische Berichte 100 (1976), p. 658.
Another possibility of synthesis of hydroxy pyridones is halogenation of the 2-halo-6-picolines side chain to obtain 2-halo-6-halomethylpyridines of formula VI (see claim 1), reaction of the halomethyl group with appropriate phenols, optionally. N-oxide oxidation and ring halogen saponification by a direct or indirect process. The reaction of the halomethyl group with the phenols is preferably carried out under the conditions described above for the reaction of the halomethylpyrones with phenols. For the transformation of pyridines to their N-oxides, inorganic or organic oxidants such as hydrogen peroxide, performic acid, peracetic acid, perbenzoic acid, 3-chloroperbenzoic acid, tert-butyl hydroperoxide are used and worked as appropriate. under catalysis with a strong acid such as sulfuric acid, perchloric acid, toluenesulfonic acid, trifluoroacetic acid and trifluoromethanesulfonic acid, preferably at temperatures between room temperature and about 100 ° C. Saponification of the ring halogen may be carried out directly, for example by reaction with bases such as sodium hydroxide, potassium hydroxide or barium hydroxide or indirectly by etherification with an alcohol again in turn. easily removable, such as tertiary butanol or 2-methoxyethanol.
The following examples illustrate typical processes for preparing the compounds of the invention of formula I.
If, according to one of the above processes, intermediate products are obtained which still contain reactive substituents on the Ar group or the pyrone ring, they may be substituted by other groups, provided that they comply with the definitions mentioned above. to 3
R e is for Ar substituents. For example, a free hydroxyl or mercapto group may subsequently be etherified or a hydroxymethyl group formed, for example by reduction of an aldehyde group, into a halomethyl group and
<img file="PT84702B_D0003.tif" />
nucleophilic substitution of halogen by reaction with a phenol or a thiophenol. Similarly, pyridine derivatives obtained by reacting the dihalopicolines of formula V with phenols or the oxidatively obtained N-oxides containing reactive substituents may be reacted analogously to substituted products of another type.
An object of the invention is also the compounds of formula V mentioned in claim 1, which constitute appropriate intermediate products.
The compounds of formula I according to the invention have extraordinary topical antimycotic properties with a broad spectrum of application against pathogenic fungi such as Dermatophytes (filiform fungi) and against fungi that attack both skin and mucous membranes, such as yeast (eg Candida). spp.), as well as against penicilia (for example Aspergillus niger). They can therefore be used to combat infections caused by these agents in human and veterinary medicine, for example in domestic animals such as dogs, cats, birds and livestock such as ruminants, horses and pigs. Application may be as free hydroxypyridone or in the form of its physiologically assimilable salts with inorganic or organic bases (e.g. fighting fungi, such as solutions, suspensions, creams, ointments, powders or suppositories (eggs). The novel preparations are distinguished in particular by their high fungicidal action as well as their long duration at the site of infection and are therefore superior to the standard preparations on the market as shown in the comparison assays described below. These compounds further have an antibacterial and antiviral action, for example against herpes viruses.
Examples • 1- 6- / 5- (2,4-dichlorobenzyl) -phenoxymethyl-1-hydroxy-3,4-dimethyl-2-pyridone (compound 7)
19.5 g of 6-chloromet-1-3,4-dimethyl-2-pyrone (compound A) and 25.3 g of 4- (2,4-dichlorobenzyl) -phenol were dissolved in 7θ ml of dimethylformamide, 20 g of finely ground potassium carbonate was added and stirred for 48 hours at room temperature. Methylene chloride (200 ml) and water (500 ml) were then added, the phases were separated, the organic phase was washed twice with 100 ml of water each time, dried and evaporated in vacuo with water. French Horn The near pure 42.7 g residue was heated by thin layer chromatography with 200 g 2-aminopyridine for 56 hours at 75 ° C and a total amount of 4.7 g hydroxylamine hydrochloride was added. , during the first 4 hours, divided into 5 portions. Methylene chloride (250 ml) was then added, washed once with dilute hydrochloric acid and twice with water, the organic phase dried and the solvent distilled off under reduced pressure. 0 39.7 g residue was recrystallized from ethylene glycol monomethyl ether and
32.5 g of pure hydroxypyridone, mp 1669 ° C · at 19:
By the procedure described in example 1, the following were obtained:
Compound 6 from 4- (4-chlorophenoxy) phenol and A compound 39 from 3- (naphtho-1-ylmethylthio) phenol and A compound 1 from 4- (4-chlorophenoxy) ) -phenol and 6-chloro methyl-4-methyl-2-pyrone (compound B) from 4- (2,4-dichlorophenoxy) -phenol and B from 4- (4-trifluoromethylphenoxy) -phenol and B compound 23 from 2,6-dichloro-4- (4-chlorophenoxy) -phenol and B compound 25 from 2,1-dichloro-4-phenylphenol and B compound 33, from 4- (4-fluorophenoxy) -phenol and B compound 34, from 3- (4-chlorophenylthio) -phenol and B-compound 35, from 3- (naphtho-1-ylmethylthio) -phenol and of B compound 2, compound 9,
<td>compound</td><td> 40,</td><td>The</td><td>leave</td><td>in</td>
<td>compound</td><td> 41,</td><td>The</td><td>leave</td><td>in</td>
<td></td><td></td><td colspan="2">from B</td><td></td>
<td>compound</td><td> 43,</td><td>The</td><td>leave</td><td>in</td>
<td>compound</td><td> 4,</td><td>The</td><td>leave</td><td>in</td>
<td>compound</td><td> 38,</td><td>The</td><td>leave</td><td>in</td>
<td>make up</td><td> 3,</td><td>The</td><td>leave</td><td>in</td>
<td>compound</td><td> 26,</td><td>The</td><td>leave</td><td>in</td>
<td></td><td></td><td>B</td><td></td><td></td>
<td>and</td><td></td><td></td><td></td><td></td>
<td>compound</td><td> 54,</td><td>The</td><td>leave</td><td>in</td>
nol and B.
2,4-dibromo-6-phenylphenol and B
4- / 4- (4-chlorophenoxy) phenoxy-phenol and
4- (4-chlorophenylthio) phenol and B 4-benzylphenol and B 2-benzylphenol and 3-4-phenylphenol and B 4- (4-bromo-2-chlorophenoxy) -phenol and
4- [α- (4-chlorophenyl) pentan-5-yl] -fe
20j 1-Hydroxy-4-methyl-6- [4- (naphtho-1-ylmethoxy) -phenoxymethyl]
-2-pyridone (compound 10)
A mixture of 100 g of 6-chloromethyl-4-methyl-2-pyrone, 210 g of hydroquinone, 132 g of potassium carbonate and 400 ml of dimethylformamide was stirred for 72 hours at room temperature and water was added. , was neutralized with hydrochloric acid, the precipitate was filtered off, washed with water and dried. Treatment with methylene chloride followed by recrystallization from acetonitrile gave 68 g of practically pure 6- (4-hydroxyphenoxymethyl) -4-methyl-2-pyridone, mp 179 ° C. g of this compound with 4 g of 1-chloromethylnaphthalene, 20 ml of dimethylformamide and 8 g of potassium carbonate for 72 hours at room temperature then diluted sodium hydroxide was added, dissolved in methylene chloride, washed with if the organic phase with water, dried and the solvent was distilled off. The 7.0 g residue was chromatographed with methylene chloride through a silica gel column to give 4.6 g of 4-methyl-6- [4- (naphthyl-1-ylmethoxy) phenoxymethyl]. Pure melting point 2-pyrone 132 ° C. This product was heated with 15 g of 2-aminopyridine at 75 ° C and 7 g of hydroxylamine hydrochloride was added over 32 hours under stirring. in four parts. After a total of 42 hours of reaction the mixture was dissolved in heat.
<img file="PT84702B_D0004.tif" />
methylene chloride, washed with dilute hydrochloric acid and water, dried, solvent distilled and the residue recrystallized from acetonitrile. 1.9 g of pure compound 10, mp 179 ° C · was isolated.
21-30:
By the procedure described in example 20, by alkylation of 6- (4-hydroxyphenoxymethyl) -4-methyl-2-pyrone intermediate with the chlorides, 2,4-dichlorobenzyl chloride, cinamyl chloride, 4-chlorobenzyl chloride, 4-trifluoromethoxybenzyl, 4-tert-butylbenzyl chloride, 3,4,5-trimethoxybenzyl chloride, 1-chloro-3- (4-chlorophenoxy) propane and 1-chloro-4- (4-chlorophenoxy) butene - (2), and the transformation of the pyrones thus obtained into hydroxypyridones gave compounds 5, 8, 15, 16, 17, 27, 46 and 52. Using catechol instead of hydroquinone and alkylating with naphtho-1-ylmethyl chloride gave the compound ηδ 19, and from sorcinol and 4-chlorobenzyl chloride gave the compound ηδ 21.
31t 6- / 2,6-dichloro -4- (naphtho-2-ylthiomethyl) -phenoxymethyl-1-hydroxy-4-methyl-2-pyridone (compound 13)
Sodium 4.8 g and 42 g of 3,5-dichloro-4-hydroxybenzaldehyde were dissolved in 250 ml of methanol, the solvent was distilled off under reduced pressure, 200 ml of dimethylformamide was added, 32 g of 6 -chloromethyl-4-methyl-2-pyrone and allowed to react for 3 days at room temperature. Dimethylformamide was then distilled during the reaction under reduced pressure, methanol was added and the mother liquor was isolated by cooling and concentration in various fractions to a total of 44 g of 6- (2). 2,6-dichloro-4-formylphenoxymethyl) -4-methyl-2-pyrone 180 ° C. 34.5 g of this compound was reduced to a mixture of 250 ml tetrahydrofuran and 100 ml methanol with 1.5 g sodium borohydride at room temperature, then warmed to 50 ° C, then 10 ml added. of concentrated sulfuric acid, most of the solvent was distilled off, the residue was stirred with water, filtered, washed with water and dried. This product (33.1 g; m.p. 154 ° C) was suspended in 200 ml of methylene chloride, 0.1 ml of dimethylformamide was added and then, at room temperature and in small portions, 11 ml of chloride. of thionyl. After 24 hours the solvent was distilled off, the residue was boiled in methanol (200 ml), cooled to 0 ° C, filtered, washed and dried. 30.1 g of pure 6- (2,6-dichloro-4-chloromethylphenoxymethyl) -4-methyl-2-pyrone, m.p. 136 ° C.
7.5 g of the compound obtained were stirred with 4 g of 2-thionaphtol, 30 ml of dimethylformamide and 7 g of potassium carbonate for 24 hours at room temperature, then added water, extracted with methylene chloride, washed with water, dried and chromatographed the solution on a silica gel column. 8.5 g of 6- [2,1-dichloro-4- (naphtho-2-ylthiomethyl) -phenoxymethyl] -4-methyl-2-pyrone (125 ° C) were obtained. This product was heated with 25 g of 2-aminopyridine at 75 ° C and a total of 8 g of hydroxylamine hydrochloride was added over 37 hours divided into 4 portions. After 48 hours of reaction, the mixture was extracted with methylene chloride, washed with dilute hydrochloric acid and water, dried and the solvent distilled off. The residue was recrystallized once from acetonitrile and once from ethyl acetate to give 2.1 g of pure compound 13, mp 138 ° C.
and 33
By a procedure analogous to that described in Example 31, compound 14 was obtained by reacting intermediate 6- (2,6-dichloro-4-chloromethylphenoxymethyl) -4-methyl-2-pyrone with 4-phenylphenol and transforming the pyrone thus obtained from hydroxypyridone. Using 4-hydroxybenzaldehyde instead of 3,5-dichloro-4-hydroxybenzaldehyde, followed by reduction by an analogous method, reaction with thionyl chloride and condensation
- l4
<img file="PT84702B_D0005.tif" />
with 4- (4-chlorophenoxy) phenol and reaction with hydroxylamine gave compound 12.
34: 6- [4- (4-chlorophenoxy) phenoxymethyl] -1-hydroxy-2-pyridone (compound 22)
30 g of 2-bromo-picoline were heated with
31.6 g N-bromosuccinimide, 0.015 g dibenzoyl peroxide and 150 ml carbon tetrachloride under ultraviolet irradiation for 30 hours at reflux, filtered, the filtrate washed once with a solution NaHCO 3 and three times with water was dried and the solvent was distilled off under reduced pressure. The residue (40.1 g) was stirred with 150 mL of hexane and after filtration 27.3 g of a mixture consisting mainly of the desired monobromomethyl compound in addition to some dibromomethyl. This mixture was stirred together with 21.4 g of 4- (4-chlorophenoxy) phenol, 20.7 g of potassium carbonate and 50 ml of dimethylformamide for 48 hours at room temperature, then 200 ml of methylene chloride, washed three times with water, concentrated the organic solution and isolated by silica gel chromatography and recrystallization from diisopropyl ether 16.3 g of 2-bromo-6- / 4- (4-chlorophenoxy) -phenoxymethyl7-pi<sup></sup>ridiculous.
15.0 g of the compound obtained was heated with a solution of 8.5 g of peracetic acid in 50 ml of acetic acid for 30 hours at 50 ° C, then the solvent portion was distilled at 40 ° C under reduced pressure. The residue was stirred three times with 200 ml of water each time and once with an aqueous sodium hydrogen carbonate solution, which was always decanted, then treated with 100 ml of diisopropyl ether, filtered and dried. if. In this way 10.2 g of almost pure N-oxide of melting point 100 ° C were obtained. 5 g of this N-oxide was heated with a solution of 1.2 g of sodium hydroxide in a mixture of 9 ml of water and 20 ml of ethylene glycol monomethyl ether at 70 ° C. Thus, by reaction with alcohol, N-oxide methoxyethyl ether, which melts at 125 ° C, was rapidly formed and then slowly saponified. After 60 hours the solvent was distilled off under reduced pressure, the residue was stirred with methylene chloride (200 mL) and dilute sulfuric acid (50 mL), the organic phase separated, dried and evaporated. The residue was recrystallized from acetonitrile to give 2.5 g of pure compound 22, mp 180 ° C.
1-Hydroxy-4-methyl-6- [3- (naphtho-1-ylmethoxy) phenylthio methyl] -2-pyridone
26 g of monotioresorcinol and 31.8 g of 6-chloromethyl-4-methyl-2-pyrone were dissolved in 100 ml of dimethylformamide, 38 g of potassium carbonate was added under stirring and ice cooling during 30 minutes, stirred for a further 4 hours at 0 ° C and for 16 hours at room temperature, then 300 ml of methylene chloride were added, stirred three times with water, and the organic phase separated. , dried and the solvent was evaporated. The residue was recrystallized from methanol and gave 44 g of 6- (3-hydroxyphenylthiomethyl) -4-methyl-2-pyrone (compound c), m.p. 129 ° C. To a solution of 8 g of sodium iodide in 200 ml of acetone was added 8.9 g of 1-chloromethylnaphthalene, stirred for 16 hours at room temperature, then 12.4 g of compound c was dissolved in the mixture. The reaction mixture was cooled to 0 ° C and 6.9 g of potassium carbonate was added gradually over 5 hours. After a total of 79 hours of reaction at 0 ° C, the solvent was distilled off under a vacuum of water, the residue was dissolved in methylene chloride, washed with water, the organic phase separated, dried. The solution was concentrated, chromatographed on a silica gel column using methylene chloride as eluent and the product was recrystallized from the major methanol fractions. 9 g of pure 4-methyl-6- [3- (naphtho-1-ylmethoxy) phenylthiomethyl] -2-pyrone, mp 139 ° C.
8.5 g of this compound was heated with 50 g of
2-aminopyridine at 75 ° C and 8.9 g of hydroxylamine hydrochloride was added slowly over 40 hours. After 60 hours of reaction, it was allowed to cool to room temperature, methylene chloride was added, washed once with dilute hydrochloric acid and three times with water, dried and the solvent was distilled off. The residue was recrystallized from ethyl acetate to give 4 g of hydroxypyridone, mp 163 ° C.
Using pyrone C (see example 35) and reacting with 4-chlorobenzyl chloride, proceeding as in example 35 gave compound 42.
37: 1-Hydroxy-4-methyl-6- [4- (4-chlorophenoxy) phenoxymethyl] -2-pyridone
171.4 g (0.5 mol) 4-methyl-6- [4- (4-chlorophenoxy) phenoxymethyl] -2-pyrone was heated in 5 ml of toluene. Then 59.9 g (0.36 Mole) of hydroxylamine sulfate and 38.3 g (θ »3 Mole) of sodium carbonate were added. Ten minutes later 59.9 g (0, 36 mol) of hydroxylamine sulfate and 3.4 g (θ, 3 mol) of sodium carbonate. After about 4 hours, heating was suspended and methylene chloride (500 ml) was added at 40 ° C. The dissolved reaction product was then filtered from the insoluble salts. The filtrate was then dried over sodium sulfate and the methylene chloride was evaporated. Stirring the residue with ethyl acetate (500 ml), the reaction product was crystallized. As a final purification dimethylformamide 1-hydroxy-4-methyl-6- [4- (4-chlorophenoxy) -phenoxymethyl] -2-pyridone was recrystallized. Yield 80.5 g (45%)} mp 130-170 ° C.
381 1-Hydroxy-4-methyl-6- [3- (phenoxyethoxy) phenoxymethyl] pyridone (compound 45)
A mixture of 80 g of 6-chloromethyl was stirred
- 17-methyl-2-pyrone, 220 g of resorcionol, 400 ml of dimethylformamide and 105 g of finely ground potassium carbonate for 72 hours at room temperature, then methylene rectum was then added, stirred. several times with water, the organic phase was dried and the solvent was distilled off under reduced pressure.
From the viscous residue (223 g) was isolated, crushing in water followed by recrystallization from methanol, 53 g of 6-45- (3-hydroxyphenoxymethyl) -4-methyl-2-pyrone (compound D) of m.p. Ç.
10 g of compound D was stirred with 11.2 g of 1-iodo-2-phenoxyethane (prepared by reacting 2-phenoxyethanol with SOClg followed by substitution of chlorine with sodium iodide in acetone), 6.9 Potassium carbonate and 50 ml of dimethylformamide for 35 hours at 50 ° C were added methylene chloride, washed several times with water, dried and the solution chromatographed on silica gel. As a major product, 10.4 g of 4-methyl-6- [3- (phenoxyethoxy) phenoxymethyl] -2-pyrone, mp 95Â ° C, was isolated. 10 g of this pyrone was heated with 50 g of 2-aminopyridine for 63 hours at 75 ° C, gradually adding 8.5 g of hydroxylamine hydrochloride, then dissolving in methylene chloride, stirring with dilute hydrochloric acid (pH 3 to 4 aqueous phase), dried, solvent distilled off and the residue was crystallized from acetonitrile. 4.3 g of pure hydroxypyridone, m.p. 144Â ° C, were obtained.
and 40i
By the procedure described in example 38, from intermediate D and 1- (4-chlorophenylthio) -4-iodobutane, compound 48 was obtained, starting from D and 2- (4-chlorophenylthio) -2 ' diethylether, compound 49 was obtained.
4l; 6- / 3- (4-chlorophenylthiopropylthio) -phenoxymethyl7<sup>-</sup>l<sup>_</sup>hydroxy-4-methyl-2-pyridone (compound 47)
A mixture of 12.6 g of monothiore18 sorcinol, 31.3 g of 1- (4-chlorophenylthio) -3-iodopropane (prepared from 4-chlorothiophenol and 1-bromo-3-doropropane followed by substitution) was stirred. chlorine per iodine, with sodium iodide in acetone), 16.6 g of potassium carbonate and 60 ml of acetone for 24 hours at room temperature, then the solvent was distilled off under reduced pressure, methylene chloride was added. , washed several times with water, dried and then isolated by silica gel chromatography using methylene chloride as eluent, 14.5 g of 3- (4-chlorophenylthiopropylthio) phenol. This product was stirred together with 9.5 g of 6-chloromethyl-4-methyl-2-pyrone, 10.4 g of potassium carbonate and 60 ml of acetone for 31 hours at 5 ° C, then distilled off. Under reduced pressure, the residue was dissolved in methylene chloride, washed several times with water, dried and chromatographed on silica gel. 11.2 g of the main fraction was heated with 5θ g of 2-aminopyridine for 65 hours at 75 ° C and a total of 12 g of hydroxylamine hydrochloride was added portionwise. Then methylene chloride was added, stirred with dilute hydrochloric acid and several times with water, dried and the solvent distilled off. The residue was 9.9 g. Treatment with methanol gave 2.7 g of pure hydroxypyridone melting point 102 ° C.
and 4.31
In the same reaction sequence and under the same conditions, from monotioresorcionol and 1- (4-chlorophenylthio) -2,2-dimethyl-3-iodopropane, compound 51 θ was obtained from monotioresorcionol and iodide. (4-chlorophenylthio) ethoxyethoxyethyl gave compound 53.
Pharmaceutical action test
In the in vitro testing of antimycotic substances, a distinction must be made between proliferating germs (Pungistase) and resting germs (Pungizidie).
- 19 t
<img file="PT84702B_D0006.tif" />
Fungidizie, tested on non-growing fungi, are used as an aggravated model. In microtiter plates a series of dilutions of the test preparations are prepared (31.25 to 0.25 µl / 1} 8 steps). Each depression shaped 'lf. of U on the plate is inoculated with 10 colony-promoting units (CFU) of the Trichophyton mentagrophytes skin fungus (NaCl physiological solution). After 18 hours of incubation at 30 ° C the germs (double centrifugation) are washed with 50% polyethylene glycol 400 and a NaCl solution and placed over malt agar to count the germ count by means of an automatic device. After incubation at 30 ° C for 3 days the colonies are counted and CFU / ml calculated. Compared to untreated controls the reduction in the number of germs in percent (control = 0%) is calculated. Pharmaceutical action is measured with standard preparations, for example clotrimazole le. Clotrimazole is the generic name of the formula compound.
<img file="PT84702B_D0007.tif" />
As shown in Table 1, the compounds according to the invention had an extremely low CFU value compared to that of the standard Clotrimazole preparation, ie the fungicidal or lethal effect of the compounds according to the invention is clearly superior to of the standard preparation.
Tab her 1
<td>Prepared</td><td>NS</td><td>CFU Number / ml 5 (n = 4)</td><td>CFU reduction over So control</td>
<td> 1</td><td></td><td> 0</td><td> 100</td>
<td> 9</td><td></td><td> 0</td><td> 100</td>
<td> 15</td><td></td><td> 1</td><td> 99,32</td>
<td> 17</td><td></td><td> 1.5</td><td> 98,98</td>
<td colspan="2">Clotrimazole</td><td> 63,6</td><td> 57</td>
<td>Controls treaties</td><td>no</td><td>U7.9</td><td> 0</td>
n = number of measured values - mean value x *
As an example of the high in vivo local efficacy of the compounds according to the invention, treatment trials are performed on experimentally infected Trichophyton mentagrophytes laboratory animals. In addition, groups of two to four guinea pigs of 4-50-500 g (white Pirbright species) were infected with 1.5 x 10 germs per animal in the epidermis, spread over 6 points of infection. The animals were taken 4 and 3 days before infection by applying a 0.3% preparation solution to 3 infection points on the right side of the back. The left side of the back, with 3 points of infection, was treated with unprepared vehicle by the same process (vehicle controls).
In addition to the animals treated with the substances according to the invention, two animals were treated with the reference substance Clotrimazole, and two infected animals remained untreated (infection controls).
As can be seen from Table 2, the compounds according to the invention had a clearly greater mycosis spread difference (nm) than that prepared for
<img file="PT84702B_D0008.tif" />
Clotrimazole, that is, the antimycotic effect of the compounds according to the invention was clearly superior to that of clotrimazole.
<td>ok t » yes Φ β Φ «Β • laughs fl</td><td>IK 1</td>
<td> 0</td><td></td>
<td>laugh</td><td>χ</td>
<td> 3</td><td>tn</td>
<td> 0</td><td>X_X</td>
<td>* laughs</td><td></td>
<td>Φ</td><td></td>
<td> ></td><td></td>
<td> +</td><td></td>
<td> 0</td><td></td>
<td>Ό</td><td>IK</td>
<td>d</td><td></td>
<td>β</td><td></td>
<td>eti</td><td></td>
<td>The</td><td></td>
<td>φ</td><td>yes</td>
<td>. β</td><td></td>
<td>sa</td><td></td>
<td>ε</td><td></td>
<td>O</td><td></td>
<td>“Laughs</td><td>zx</td>
<td>o 3</td><td>cn</td>
<td>P o</td><td></td>
<td>wi Vf</td><td></td>
<td>φ Φ</td><td></td>
<td>ε></td><td></td>
<td>«J</td><td></td>
<td>β ®</td><td></td>
<td>Ρ Ό</td><td></td>
<td>I'm</td><td></td>
<td>cd w</td><td>rri</td>
<td>H "</td><td>IK</td>
<td>(d rri</td><td></td>
<td>' O</td><td></td>
<td>β</td><td></td>
<td>tn p</td><td></td>
<td>«Pi</td><td></td>
<td>co the</td><td>yes</td>
<td>0 o</td><td></td>
<td>O</td><td></td>
<td>• laughs</td><td>cn</td>
<td>s</td><td>• laughs</td>
<td>Φ</td><td>CD</td>
<td>Ό</td><td>ε</td>
<td></td><td>• laughs</td>
<td>Hello</td><td>yes</td>
<td> 3</td><td>CD</td>
<td>O</td><td></td>
<td>Ό</td><td></td>
<td>all</td><td></td>
<td>β</td><td></td>
<td>CD</td><td></td>
<td>The</td><td>Hello</td>
<td>φ</td><td>The</td>
<td>β</td><td></td>
<td>The</td><td></td>
<td> 0</td><td></td>
<td>icd</td><td></td>
<td>o></td><td></td>
<td>cm cd</td><td></td>
<td>β</td><td></td>
<td>cd p</td><td></td>
<td>laughed</td><td></td>
<td>φ Φ</td><td></td>
<td>fl O</td><td></td>
<td>cd</td><td></td>
<td>gri 0</td><td></td>
O
<td>O</td><td>CM</td><td>O</td><td> 1></td><td>O</td>
<td>et</td><td>et</td><td>et</td><td>et</td><td>et</td>
<td>O</td><td> 4</td><td>O</td><td></td><td>O</td>
<td>fl</td><td>»N</td><td> 4</td><td>O</td><td>O</td>
<td>laugh</td><td>laugh</td><td>tri</td><td>CM</td><td>laugh</td>
<td>X — z</td><td>XX</td><td></td><td>XZ</td><td>X »z</td>
<td>fl</td><td> 4</td><td>Ç\</td><td>CM</td><td>m</td>
<td>et</td><td> •</td><td> *</td><td>et</td><td> •</td>
<td>in</td><td>W \</td><td> 4</td><td> !></td><td>cn</td>
<td></td><td>x</td><td></td><td></td><td>z — X</td>
<td> -4</td><td>CM</td><td> 00</td><td> 4</td><td> 00</td>
<td>et</td><td>• t</td><td>et</td><td>et</td><td> «·</td>
<td>cn</td><td>laugh</td><td>tri</td><td>O</td><td>H</td>
<td>X— ''</td><td>X — Z</td><td></td><td>XuzZ</td><td>xz</td>
<td>CM</td><td>cn</td><td>H</td><td> 00</td><td> 4</td>
<td>et</td><td> ·»</td><td> ·»</td><td>et</td><td>• t</td>
<td>O\</td><td> 00</td><td>O\</td><td>r-</td><td>O laugh</td>
<td>CM laugh</td><td>CM laugh</td><td>\O</td><td>fl</td><td>CM tri</td>
<td></td><td></td><td></td><td></td><td>X — X</td>
<td>I></td><td>CM</td><td> 4·</td><td>m</td><td>O</td>
<td>et</td><td> *</td><td>et</td><td>et</td><td> *</td>
<td>CM</td><td>CM</td><td>cn</td><td>H</td><td>CM</td>
<td></td><td></td><td></td><td>S ^.</td><td></td>
<td> 00</td><td> 1></td><td>O</td><td>O</td><td>O\</td>
<td>et</td><td>and"</td><td>• k</td><td>et</td><td>et</td>
<td> 4</td><td>cn</td><td> 4</td><td>in</td><td>cn</td>
<td>laugh</td><td>tri</td><td>laugh</td><td>laugh</td><td>laugh</td>
<td>CM I will</td><td>CM laugh</td><td>fl</td><td>fl</td><td>CM laugh</td>
<td> 4</td><td> 4</td><td>CM</td><td>CM</td><td> 4</td>
Ch rri Ch O Ά CM rri et iri í>
et cn rri
CM laughs
CM
QC
O laughs
Ό * Φ ε
laugh
O
No laughs
P
The rri
The id
O • laughs
β * φ a
cn *
O
K
CM
Φ
Ό
Laughs
O β
-μ
Pi o
O
The icd
O) o
• fi • ri t »©
<td>β</td><td colspan="2"> 0</td>
<td>O</td><td></td><td>icd</td>
<td>laugh</td><td></td><td>β</td>
<td>CD</td><td></td><td>Ό</td>
<td> ></td><td>O</td><td>CD</td>
<td></td><td>• laughs</td><td>The</td>
<td>φ</td><td>Ό</td><td></td>
<td>Ό</td><td>* Φ</td><td> 0</td>
<td></td><td>ε</td><td>• laughs</td>
<td>O</td><td></td><td> ></td>
<td>β</td><td>β</td><td>cn</td>
<td>Φ</td><td>ο</td><td>φ</td>
<td>ε</td><td>tri</td><td>Ό</td>
<td> *3</td><td>CD</td><td></td>
<td>yes</td><td> ></td><td>II</td>
<td>ll</td><td>II</td><td>tn</td>
<td>yes</td><td>ΐκ</td><td>χ — z</td>
CLAIMS
Contents12
8 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8
46 members in 22 offices
Priority claims2
| Document | Office | Kind | Date |
|---|---|---|---|
| 3613061 | Germany | A | |
| 3626211 | Germany | A |
Members46
| Document | Office | Kind | |
|---|---|---|---|
| DK198387D0 | Denmark | D0 | |
| NO871602D0 | Norway | D0 | |
| FI871699A0 | Finland | A0 | |
| PT84702A | Portugal | A | |
| IE871009L | Ireland | L | |
| DK198387A | Denmark | A | |
| FI871699A | Finland | A | |
| FI871699A7 | Finland | A7 | |
| NO871602L | Norway | L | |
| EP0241918A2 | European Patent Office (EPO) | A2 | |
| AU7171787A | Australia | A | |
| DE3613061A1 | Germany | A1 | |
| IL82231A0 | Israel | A0 | |
| IL82231D0 | Israel | D0 | |
| JPS62249974A | Japan | A | |
| KR870010001A | Republic of Korea | A | |
| HUT43824A | Hungary | A | |
| ZA872745B | South Africa | B | |
| DE3626211A1 | Germany | A1 | |
| ATA258387A | Austria | A | |
| US4797409A | United States of America | A | |
| EP0241918A3 | European Patent Office (EPO) | A3 | |
| AT388551B | Austria | B | |
| HU198020B | Hungary | B | |
| NZ220020A | New Zealand | A | |
| PT84702BThis record | Portugal | B | |
| PH24106A | Philippines | A | |
| AU602684B2 | Australia | B2 | |
| JPH03864B2 | Japan | B2 | |
| IL82231A | Israel | A | |
| EP0241918B1 | European Patent Office (EPO) | B1 | |
| CA1302415C | Canada | C | |
| AT76638T | Austria | T | |
| ATE76638T1 | Austria | T1 | |
| FI86635B | Finland | B | |
| DE3779352D1 | Germany | D1 | |
| NO170540B | Norway | B | |
| FI86635C | Finland | C | |
| NO170540C | Norway | C | |
| AR242187A1 | Argentina | A1 | |
| GR3005465T3 | Greece | T3 | |
| DK167494B1 | Denmark | B1 | |
| ES2041656T3 | Spain | T3 | |
| MX6093A | Mexico | A | |
| IE59965B1 | Ireland | B1 | |
| KR950007754B1 | Republic of Korea | B1 |
Numbers
- Application
- 84702
Titles2
- Portuguese
- PROCESSO PARA A PREPARACAO DE 1-HIDROXI-2-PIRIDONAS, DE COMPOSICOES FARMACEUTICAS QUE AS CONTEM E DOS PRODUTOS INTERMEDIARIOS PARA A SUA PREPARACAO
- English
- PROCESS FOR THE PREPARATION OF 1-HYDROXY-2-PYRIDONES, OF THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
Classification
- CPC, 2
- C07D213/89
- C07D309/38
- IPC, 3
- A61K31 44
- C07D213 89
- C07D309 38
